Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Date:5/15/2008

from $5.7 million in the same period last year. The decrease was due primarily to restructuring of personnel and reduced general and administrative expenses.

The Company's net loss for the first quarter of 2008 was $4.8 million, compared to $6.0 million for the same period in 2007. Basic and diluted net loss for the first quarter of 2008 was $0.76 per share based on 6.38 million total shares outstanding, compared to a basic and diluted net loss of $1.54 per share based on 3.92 million total shares outstanding for the same period in 2007. Earnings per share calculations are on a post reverse stock split basis.

At March 31, 2008, the Company's cash, short- and long-term investments totaled $14.3 million, compared to $20.4 million at December 31, 2007. Net cash used in operating activities in the first quarter of 2008 was $5.5 million. The semi-annual payment of interest of approximately $0.6 million on the senior convertible note is due during the first and third quarters, which results in higher net cash outflows for these quarters. Vermillion continues to diligently manage expenses and cash utilization.

Recent Highlights and Accomplishments

During the first and into the second quarter of the year, Vermillion achieved numerous milestones in its three leading diagnostic programs and continued to progress in its corporate development efforts.

-- PAD Diagnostic Program

* Established a clinical steering committee to provide advice on

studies to support registration of VASCLIR with the FDA and to

further potential market adoption.

* Presented data from a study providing further confirmation that the

Company's test may aid in the diagnosis of PAD. The research, which

was presented at the American College of Cardiology 57th Annual

Scientific Session, suggests that such a test may be useful in

helping determine a patient's risk for de
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 Staying true to their mission ... digital product that makes the world a better place, ... Standards Institute (GBSI) to redesign their website ( http://www.gbsi.org ... importantly, strategy-based. , "Biomedical research is not always an ... to promote it in a narrative way on a ...
(Date:4/21/2015)... YORK , April 21, 2015 AbilTo, ... today that its abstract submission has been accepted as ... Association,s (ADA) annual meeting taking place on June 5-6, 2015 ... According to the American Diabetes Association, the cost ... was $245 billion. As a result of increased inpatient, ...
(Date:4/21/2015)... 2015 Invetech , a global ... and contract manufacturing, and  NanoCellect Biomedical, a ... cell sorting technology for life science researchers, today ... cytometry platform. Headquartered in ... a microchip-based cell sorting technology. NanoCellect,s flow cytometry ...
(Date:4/21/2015)... 21, 2015 Immune Pharmaceuticals Inc., or "Immune" ... Directors has elected Rene-Pierre Azria as a ... Committee, with oversight on strategic and financial transactions. Mr. ... Committee, the Compensation Committee and the Corporate Governance and ... commented: "I have a long-time interest in Life Sciences ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today announced ... results for 2007 after the market closes on Tuesday,February ... at,5:00 p.m. EST, 2:00 p.m. PST, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... In a letter to,Governor Jennifer Granholm today, ... Governor,s State of the State Address,wherein she called ... is the,statewide association for Michigan,s life sciences industry., ... the legislature, to diversify,the state,s economy by focusing ...
... Md., Jan. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... commercializing novel anti-infective products, today,announced that it has ... and warrants, resulting in the receipt of $21 ... use the proceeds from the financing to support,the ...
Cached Biology Technology:CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008 2MichBio Responds to Governor's Plan to Repeal Tort Reform Laws 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... that acts as a "master switch" in certain white ... The study, published in the journal Nature Immunology ... diseases such as rheumatoid arthritis that involve excessive inflammation. ... body uses against harmful stimuli such as infections or ...
... WASHINGTON, Jan. 15, 2011 In research described as "a ... reporting that cigarette smoke begins to cause genetic damage within ... Their report, the first human study to detail the ... cancer, appears in Chemical Research in Toxicology , one ...
... 2010) The kidney is made up of roughly 1 ... waste products from the blood, recycle some substances to be ... segment of nephrons, called the distal nephron, helps set blood ... Today scientists at The University of Texas Health ...
Cached Biology News:Scientists find the 'master switch' for key immune cells in inflammatory diseases 2'A stark warning:' Smoking causes genetic damage within minutes after inhaling 2
...
...
...
... This antibody recognizes murine IRF7 ... with other related IRF proteins. ... murine IRF7 protein was confirmed ... the 293T cells transfected with ...
Biology Products: